A 19 item, self-reported questionnaire assessing chronic cough and its impact on quality of life for patients with chronic respiratory disease.
Not a CDE -- last searched 11/1/2024
19
5 minutes
Adult
18 - 64
yearsElderly Adult
65 +
yearsDr. Alaina Bell, PT, DPT, Emma Burch, SPT, Kim Khong, SPT, Haley Langston, SPT, & Christopher Nguyen, SPT, PCOM Georgia
None found -- last searched 11/1/2024
Chronic Obstructive Pulmonary Disease (COPD) with chronic cough: (Berkhof et al., 2012; n = 54; mean age = 68 (10) years; mean pack-years = 36 (22))
COPD: (S?nnerfors et al., 2018; n = 86; mean age = 71.33 (6.8) years; female = 63; Swedish translation of LCQ)
Non-cystic Fibrosis Bronchiectasis: (Munoz et al, 2016; n = 259, mean age = 58.37 (18.1) years, female = 154 (59%), Spanish translation of LCQ)
COPD with chronic cough: (Berkhof et al., 2012)
COPD: (S?nnerfors et al, 2018; Swedish translation of LCQ)
Non-cystic Fibrosis Bronchiectasis: (Munoz et al, 2016; Spanish translation of LCQ)
Non-cystic Fibrosis Bronchiectasis: (Munoz et al, 2016; Spanish translation of LCQ)
COPD with chronic cough: (Berkhof et al, 2012; tested at 0 and 2 weeks)
COPD: (Kurhan et al., 2018; n = 150 (75 COPD patients over age 40, mean age = 62.32 (7.8), female = 94.6%; and 75 control subjects, mean age = 55.45 (8.0), female = 50.7%; Turkish translation of LCQ)
COPD: (S?nnerfors et al, 2018; Swedish translation of LCQ)
Non-cystic Fibrosis Bronchiectasis: (Murray et al, 2009; n = 120 (51 with severe bronchiectasis, male = 25 (49%), median age = 68 (IQR = 60-74); 29 w/moderate, male = 10 (34.5%), median age = 69.5 (IQR = 56.2-77.2); and 40 w/mild, male = 16 (40%), median age = 67 (IQR = 59-76.7); test repeated 6 months after completion of initial questionnaire)
Non-cystic Fibrosis Bronchiectasis: (Munoz et al, 2016; Spanish translation of LCQ)
Chronic Cough: (Birring et al., 2003; n = 104; chronic cough outpatients)
Unexplained Chronic Cough: (Nguyen et al., 2022; n = 253, mean age = 60.2 (9.9), female = 76.3%; 97.6 % had used medication to treat their cough within 30 days of screening)
Chronic Cough LCQ: (Birring et al., 2003)
Unexplained Chronic Cough: (Nguyen et al., 2022)
Unexplained Chronic Cough: (Nguyen et al., 2022)
Unexplained Chronic Cough: (Nguyen et al., 2022; n = 61)
Chronic Cough: (Birring et al., 2003)
Chronic Cough LCQ: (Birring et al., 2003)
Unexplained Chronic Cough: (Nguyen et al., 2022)
Concurrent validity:
Chronic Cough: (Birring et al., 2003; LCQ2 is the final 19-item version of LCQ)
Unexplained Chronic Cough: (Nguyen et al., 2022)
Convergent validity:
Unexplained Chronic Cough: (Nguyen et al., 2022)
Discriminant validity:
Unexplained Chronic Cough: (Nguyen et al., 2022)
Known-groups validity: LCQ scores at baseline by CSD total score groups at baselinea
LCQ Domain | CSD tertile Group 1 Mean (SE) | CSD tertile Group 2 Mean (SE) | CSD tertile Group 3 Mean (SE) | Overall F value (p) |
Physical | 5.0 (0.10) | 4.6 (0.10) | 3.7 (0.10) | 40.20 (<0.0001) |
Psychological | 4.3 (0.13) | 3.6 (0.12) | 3.2 (0.13) | 16.41 (<0.0001) |
Social | 4.3 (0.13) | 3.5 (0.12) | 3.0 (0.12) | 29.82 (<0.0001) |
Total score | 13.5 (0.30) | 11.7 (0.29) | 9.9 (0.30) | 35.68 (<0.0001) |
CSD = Cough Severity Diary; LCQ = Leicester Cough Questionnaire; SE = Standard error
aParticipants were stratified into tertiles using sample distribution according to CSD score at baseline. Group 1 (n = 76) = participants with the lowest CSD scores (i.e., lowest cough severity), Group 2 (n = 85) = participants in the middle third of CSD scores, and Group 3 (n = 78) = those with the highest CSD scores (i.e., highest cough severity).
Chronic Cough: (Birring et al., 2003)
Unexplained Chronic Cough: (Nguyen et al., 2022)
Chronic Cough: (Birring et al., 2003)
Unexplained Chronic Cough: (Nguyen et al., 2022)
Berkhof, F. F., Boom, L. N., ten Hertog, N. E., Uil, S. M., Kerstjens, H. A., & van den Berg, J. W. (2012). The validity and precision of the Leicester Cough Questionnaire in COPD patients with chronic cough. Health and quality of life outcomes, 10, 4.
Birring, S. S., Prudon, B., Carr, A. J., Singh, S. J., Morgan, M. D., & Pavord, I. D. (2003). Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax, 58(4), 339–343.
Kurhan, F., G?ktalay, T., Havlucu, Y., Sar?, S., Yorganc?o?lu, A., ?elik, P., & ?akar Co?kun, A. (2018). The validity and reliability of the Turkish version of the Leicester Cough Questionnaire in COPD patients. Turkish Journal of Medical Sciences, 48(4), 811–816.
Mu?oz G, Buxó M, de Gracia J, et al. (2016). Validation of a Spanish version of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Chron Respir Dis., 13(2):128-136.
Murray, M. P., Turnbull, K., MacQuarrie, S., Pentland, J. L., & Hill, A. T. (2009). Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. The European respiratory journal, 34(1), 125–131.
Nguyen AM, Schelfhout J, Muccino D, et al. (2022). Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough. Ther Adv Respir Dis., 16: 1-13.
S?nnerfors, P., Faager, G., & Einarsson, U. (2018). Translation of the Leicester Cough Questionnaire into Swedish, and validity and reliability in chronic obstructive pulmonary disease. Disability and rehabilitation, 40(22), 2662–2670.
Vodanovich, D. A., Bicknell, T. J., Holland, A. E., et al. (2015). Validity and Reliability of the Chronic Respiratory Disease Questionnaire in Elderly Individuals with Mild to Moderate Non-Cystic Fibrosis Bronchiectasis. Respiration, 90(2):89-96.
We have reviewed more than 500 instruments for use with a number of diagnoses including stroke, spinal cord injury and traumatic brain injury among several others.